Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ROS1-fusion Positive Tumor”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04395677
What this trial is testing

AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Who this might be right for
Non Small Cell Lung Cancer
Nuvation Bio Inc. 173
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Not applicableLooking for participantsNCT06781905
What this trial is testing

Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway

Who this might be right for
Metastatic Lung CancerMetastatic Lung Cancer With ALK/ROS1 Fusion
Hospices Civils de Lyon 20
Not applicableLooking for participantsNCT07199959
What this trial is testing

Study on the Mechanism of Acquired Resistance of Entrectinib

Who this might be right for
ROS1 Fusion PositiveNon Small Cell Lung Cancer
Fudan University 38
Large-scale testing (Phase 3)Looking for participantsNCT05770544
What this trial is testing

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

Who this might be right for
Haematological MalignancyMalignancyMalignant Neoplasm+8 more
Cancer Research UK 30
Not applicableUnknownNCT04921553
What this trial is testing

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Who this might be right for
CancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more
Centre Leon Berard 500
Not applicableLooking for participantsNCT04900935
What this trial is testing

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Who this might be right for
Stage IV Non-small Cell Lung CancerTargeted TherapyNonsmall Cell Lung Cancer+5 more
Massachusetts General Hospital 70
Not applicableStudy completedNCT03497624
What this trial is testing

ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors

Who this might be right for
ROS1-fusion Positive Tumor
Addario Lung Cancer Medical Institute 5
Testing effectiveness (Phase 2)Ended earlyNCT02587650
What this trial is testing

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Who this might be right for
ALK Fusion Protein ExpressionBRAF wt AlleleInvasive Skin Melanoma+12 more
University of California, San Francisco 1
Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Early research (Phase 1)Looking for participantsNCT06128148
What this trial is testing

Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

Who this might be right for
Protein Kinase InhibitorsOther Protocol Specified CriteriaLung Neoplasms+1 more
Guangzhou JOYO Pharma Co., Ltd 101
Testing effectiveness (Phase 2)Looking for participantsNCT04996121
What this trial is testing

XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid TumorsLocally Advanced or Metastatic Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 360
Not applicableNot Yet RecruitingNCT07599007
What this trial is testing

Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 10
Testing effectiveness (Phase 2)WithdrawnNCT03868423
What this trial is testing

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Who this might be right for
Advanced Malignant NeoplasmALK Fusion Protein ExpressionALK Gene Amplification+8 more
Sameek Roychowdhury
Testing effectiveness (Phase 2)Looking for participantsNCT01639508
What this trial is testing

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Who this might be right for
Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 86
Large-scale testing (Phase 3)Looking for participantsNCT07154706
What this trial is testing

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc. 180